Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Frontiers in Public Health|June 5, 2023
Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programsTom Hughes, Ashley E L Anderson, Ali A Habib, et al.
Advances in Therapy|October 29, 2024
Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia GravisA Gordon Smith, Gil I Wolfe, Ali A Habib, et al.
European Journal of Neurology|August 4, 2025
Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PROHenry J Kaminski, Carlo Antozzi, Ali A Habib, et al.
Journal of Neuromuscular Diseases|March 4, 2025
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extensionAli A Habib, Artur Drużdż, Julian Grosskreutz, et al.
Journal of Neuromuscular Diseases|March 4, 2025
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensionsVera Bril, Artur Drużdż, Julian Grosskreutz, et al.
Journal of Neurology|March 19, 2025
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 studyVera Bril, Artur Drużdż, Julian Grosskreutz, et al.
Neurology|April 19, 2023
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical TrialsJeffrey T Guptill, Michael Benatar, Volkan Granit, et al.
Therapeutic Advances in Neurological Disorders|July 2, 2026
Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensionsVera Bril, Artur Drużdż, Julian Grosskreutz, et al.
The Lancet. Neurology|April 14, 2023
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 studyVera Bril, Artur Drużdż, Julian Grosskreutz, et al.
Muscle & Nerve|September 11, 2023
Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practiceNakul Katyal, Karen Halldorsdottir, Raghav Govindarajan, et al.
Pageof 5